AB
AEON BiopharmaClinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a biosimilar to Botox, for therapeutic indications like cervical dystonia and chronic migraine.
1 Pulse story
CD
Chai DiscoveryChai Discovery builds generative AI foundation models that predict and design protein and antibody structures to accelerate pre-clinical drug discovery.
2 Pulse stories
Total Raised
$600M
AEON BiopharmaChai Discovery
Last Valuation
$3.8B
AEON BiopharmaChai Discovery
Biotech
Sector
Biotech
2013
Founded
2024
Irvine, California
HQ
San Francisco, CA
Public (AEON)
Status
Private
AEON Biopharma investors
No investors on record.
Chai Discovery investors
Index VenturesSequoia CapitalDimensionKleiner Perkins
Data from Value Add Pulse coverage and company research — see the full threads for AEON Biopharma and Chai Discovery.